Neil Kumar, BridgeBio CEO (Jeff Rumans for Endpoints News)

Shrink­ing Bridge­Bio con­firms lay­offs, de­tails out-li­cens­ing plans for its ‘re­struc­tur­ing ini­tia­tive’

In the wake of Bridge­Bio’s Phase III fail for its lead drug late last year, the com­pa­ny has been tight-lipped about its “re­struc­tur­ing ini­tia­tive.”

How­ev­er, the com­pa­ny’s Q1 fi­nan­cial re­port out­lines a sig­nif­i­cant shift for the biotech — few­er peo­ple, few­er build­ings, and more out-li­cens­ing part­ners.

Just over a month ago, Bridge­Bio laid off a num­ber of em­ploy­ees, though it would not spec­i­fy ex­act­ly how many, End­points News re­port­ed. It al­so saw its chief strat­e­gy of­fi­cer Cameron Tur­tle leave af­ter just over a year in the po­si­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.